Clinical trial

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

NCT00168922

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Bendamustin/Ribomustin Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2001-02-01

PhasePHASE2

Conditions

Recurrent Small Cell Lung Cancerunresolved

Interventions

Bendamustin/RibomustinDRUG

Sponsors & collaborators

Charite University, Berlin, Germanylead sponsor

ribosepharm GmbHcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00168922 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.